LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
-5.46%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$111M
AUM Growth
+$111M
(-5.6%)
Cap. Flow
+$93.5K
Cap. Flow
% of AUM
0.08%
Top 10 Holdings %
Top 10 Hldgs %
96.74%
Holding
12
New
–
Increased
6
Reduced
4
Closed
–
Top Buys
| 1 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$8.13M |
| 2 |
Passage Bio
PASG
|
$2.91M |
| 3 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$1.41M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
$673K |
| 5 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$336K |
Top Sells
| 1 |
Merus
MRUS
|
$7.77M |
| 2 |
BLU
BELLUS Health Inc.
BLU
|
$4.75M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$923K |
| 4 |
Immunic
IMUX
|
$101K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLU
1
DELISTED
BELLUS Health Inc.
BLU
| $25.2M | 22.69% | 2,382,127 -449,461 | -16% | -$4.75M |
|
|
ALPN
2
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $22M | 19.85% | 3,056,420 +1,129,551 | +59% | +$8.13M |
|
|
KNTE
3
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $20M | 18.05% | 1,674,677 | – | – |
|
|
4
Merus
MRUS
$4.98B
| $12.3M | 11.08% | 613,071 -388,146 | -39% | -$7.77M |
|
|
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
| $8.14M | 7.34% | 2,325,833 -263,846 | -10% | -$923K |
|
|
JBIO
6
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $4.58M | 4.13% | 276,447 +84,882 | +44% | +$1.41M |
|
|
PRDS
7
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $4.21M | 3.8% | 2,275,732 +95,172 | +4% | +$176K |
|
|
PVLA
8
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $4.04M | 3.65% | 3,515,140 +291,806 | +9% | +$336K |
|
|
9
Passage Bio
PASG
$22.7M
| $3.44M | 3.1% | 2,752,422 +2,331,012 | +553% | +$2.91M |
|
|
10
Immunic
IMUX
$80.9M
| $3.39M | 3.06% | 1,072,288 -31,953 | -3% | -$101K |
|
|
THRX
11
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $2.93M | 2.64% | 504,862 | – | – |
|
|
OTIC
12
DELISTED
Otonomy, Inc.
OTIC
| $682K | 0.62% | 2,312,880 +2,282,880 | +7,610% | +$673K |
|